Momenta To Pay $35M To Exit Blood Clot Drug Antitrust Suit

By Adam Lidgett · December 11, 2019, 6:41 PM EST

Momenta has agreed to pay $35 million to exit a class action brought by a group of drug buyers accusing the company and Sandoz of conspiring to monopolize the blood clot...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee v. Momenta Pharmaceuticals, Inc. et al

Case Number

Court

Tennessee Middle

Nature of Suit

Anti-Trust

Date Filed

October 14, 2015

Recent Articles By Adam

April 11, 2025
Foreign Cos. Say Anti-Choking Device Patent Is Invalid
April 11, 2025
Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement
April 08, 2025
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030
April 07, 2025
Incyte Can't Get Pretrial Win In Novartis Royalty Fight
April 03, 2025
Texas Appeals Court Backs UT Royalty Award In Pet Co. Suit
March 27, 2025
Fitch Even Sues Ex-IP Client In Effort To End Malpractice Case
March 24, 2025
Amgen Wants $50M Leukemia Drug Patent Verdict Thrown Out
March 18, 2025
Bausch Eye Vitamin Case Should Go To Jury, Judge Says
March 18, 2025
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents
January 22, 2025
Vanda Loses Takings Clause Arguments In Trade Secret Fight